Dr. Amy S. Paller

Pediatrics
676 N St Clair St Ste 1600, Arkes Pavilion, 
Chicago, IL 
Clinical Trials:Currently Recruiting for 2 Trials
47 Years of Experience
676 N St Clair St Ste 1600, Arkes Pavilion, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Amy Paller is a Pediatrics provider in Chicago, Illinois. Dr. Paller has been practicing medicine for over 47 years and is rated as an Experienced provider by MediFind in the treatment of Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limbs Defects. Her top areas of expertise are Ectodermal Dysplasias, Clouston Syndrome, Plaque Psoriasis, Discoid Lupus Erythematosus (DLE), and Gastrostomy.

Her clinical research consists of co-authoring 474 peer reviewed articles and participating in 21 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Stanford University School Of Medicine, 1978
Residency
McGaw Medical Center of Northwestern University
Specialties
Pediatrics
Licenses
Pediatrics in IL
Board Certifications
American Board Of Dermatology - Dermatology (Certified)
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

676 N St Clair St Ste 1600, Arkes Pavilion, Chicago, IL 60611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Systems Biology of Early Atopy
Systems Biology of Early Atopy
Enrollment Status: Recruiting
Publish Date: May 16, 2025
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment
Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment
Enrollment Status: Completed
Publish Date: July 29, 2025
Intervention Type: Other
Determining Effects of Superfine Sheep Wool in INfantile Eczema (DESSINE 2): a Multicentre Randomized Crossover Study
Determining Effects of Superfine Sheep Wool in INfantile Eczema (DESSINE 2): a Multicentre Randomized Crossover Study
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Other
Study Phase: Not Applicable
Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis SUB-STUDY: Defining the Predictive Non-Invasive Biomarkers for Pediatric Atopic Dermatitis (Funded by Regeneron Pharmaceuticals, Inc.)
Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis SUB-STUDY: Defining the Predictive Non-Invasive Biomarkers for Pediatric Atopic Dermatitis (Funded by Regeneron Pharmaceuticals, Inc.)
Enrollment Status: Active_not_recruiting
Publish Date: April 27, 2025
Defining the Skin and Blood Biomarkers of Ichthyosis
Defining the Skin and Blood Biomarkers of Ichthyosis
Enrollment Status: Enrolling_by_invitation
Publish Date: April 24, 2025
An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses.
An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses.
Enrollment Status: Completed
Publish Date: February 12, 2025
Intervention Type: Drug
Study Drug: Ustekinumab
Study Phase: Early Phase 1
Open Label Treatment of Beremagene Geperpavec (B-VEC)
Open Label Treatment of Beremagene Geperpavec (B-VEC)
Enrollment Status: Completed
Publish Date: April 09, 2024
Intervention Type: Biological
Study Drug: Open Label Topical Beremagene Geperpavec (B-VEC)
Study Phase: Phase 3
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase III Efficacy and Safety Study of Beremagene Geperpavec (B-VEC, Previously KB103) for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)
A Phase III Efficacy and Safety Study of Beremagene Geperpavec (B-VEC, Previously KB103) for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)
Enrollment Status: Completed
Publish Date: February 17, 2023
Intervention Type: Biological, Other
Study Drug: Topical Beremagene Geperpavec
Study Phase: Phase 3
A Randomized,Single-Blind, Placebo-controlled, Self-matched Pairing, Independent Evaluated Study to Evaluate the Efficacy and Safety of RGN-137 Topical Gel in Subjects With Junctional and Dystrophic Epidermolysis Bullosa (CELEB)
A Randomized,Single-Blind, Placebo-controlled, Self-matched Pairing, Independent Evaluated Study to Evaluate the Efficacy and Safety of RGN-137 Topical Gel in Subjects With Junctional and Dystrophic Epidermolysis Bullosa (CELEB)
Enrollment Status: Terminated
Publish Date: August 22, 2022
Intervention Type: Drug
Study Drug: RGN-137
Study Phase: Phase 2
A Smart, Always -On Health Monitoring System, Sub-Study: No Strings Attached: Wireless Sensor Technology in the Prentice NICU
A Smart, Always -On Health Monitoring System, Sub-Study: No Strings Attached: Wireless Sensor Technology in the Prentice NICU
Enrollment Status: Completed
Publish Date: June 14, 2022
Intervention Type: Device
Genetic Analysis of Pediatric Psoriasis
Genetic Analysis of Pediatric Psoriasis
Enrollment Status: Completed
Publish Date: April 20, 2022
Intervention Type: Other
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum
Enrollment Status: Completed
Publish Date: December 14, 2021
Intervention Type: Combination product
Study Phase: Phase 3
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Pilot Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis
An Open-Label, Pilot Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 1
AAD-PEPR: Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments Sub-Study: Clinically Relevant Endpoints in Atopic Dermatitis in Children (CREAD-C)--Funded by Regeneron
AAD-PEPR: Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments Sub-Study: Clinically Relevant Endpoints in Atopic Dermatitis in Children (CREAD-C)--Funded by Regeneron
Enrollment Status: Completed
Publish Date: October 09, 2020
Intervention Type: Other
Study Phase: Not Applicable
Pre-SunBeam Pilot Study: Comparative Assessment of TEWL Measurements From AquaFlux vs. Handheld GPSkin Pro in Young Children With and Without AD
Pre-SunBeam Pilot Study: Comparative Assessment of TEWL Measurements From AquaFlux vs. Handheld GPSkin Pro in Young Children With and Without AD
Enrollment Status: Completed
Publish Date: September 07, 2020
Intervention Type: Device
Study Phase: Not Applicable
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa
Enrollment Status: Completed
Publish Date: April 09, 2020
Intervention Type: Drug
Study Phase: Phase 3
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
Enrollment Status: Terminated
Publish Date: November 05, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 19 Less Clinical Trials

474 Total Publications

Development and Validation of a Scale to Assess Epidermolysis Bullosa Simplex Severity.
Development and Validation of a Scale to Assess Epidermolysis Bullosa Simplex Severity.
Journal: JAMA dermatology
Published: October 15, 2025
Similar Doctors
Advanced in Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limbs Defects
Dr. Gifty Bhat
Medical Genetics | Pediatrics
Advanced in Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limbs Defects
Dr. Gifty Bhat
Medical Genetics | Pediatrics
1801 W Taylor St Ste 2e, Ui Health Occ, 
Chicago, IL 
 (4.0 miles away)
312-996-7416
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Gifty Bhat is a Medical Genetics specialist and a Pediatrics provider in Chicago, Illinois. Dr. Bhat is rated as a Distinguished provider by MediFind in the treatment of Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limbs Defects. Her top areas of expertise are Microcephaly, HNRNPH2-Related Disorder, Chromosome 6q Duplication, and Chromosome 8p Deletion. Dr. Bhat is currently accepting new patients.

Advanced in Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limbs Defects
Dr. Mindy H. Li
Medical Genetics | Pediatrics
Advanced in Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limbs Defects
Dr. Mindy H. Li
Medical Genetics | Pediatrics
225 E Chicago Ave, 
Chicago, IL 
 (0.4 miles away)
312-227-6120
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Mindy Li is a Medical Genetics specialist and a Pediatrics provider in Chicago, Illinois. Dr. Li is rated as an Advanced provider by MediFind in the treatment of Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limbs Defects. Her top areas of expertise are Delayed Growth, Isolated Ectopia Lentis, Costello Syndrome, and Fetal Akinesia Sequence. Dr. Li is currently accepting new patients in some locations.

Advanced in Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limbs Defects
Dr. Joshua J. Baker
Medical Genetics | Pediatrics
Advanced in Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limbs Defects
Dr. Joshua J. Baker
Medical Genetics | Pediatrics

Lurie Children's Medical Group Inc.

225 E Chicago Ave, 
Chicago, IL 
 (0.4 miles away)
312-227-6415
Languages Spoken:
English
See accepted insurances

Joshua Baker is a Medical Genetics specialist and a Pediatrics provider in Chicago, Illinois. Dr. Baker is rated as a Distinguished provider by MediFind in the treatment of Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limbs Defects. His top areas of expertise are Ornithine Transcarbamylase Deficiency, Urea Cycle Disorders (UCD), Acid Sphingomyelinase Deficiency (ASMD), and Propionic Acidemia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Paller's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 23 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile